NEW YORK (GenomeWeb News) — The Vanderbilt-Ingram Cancer Center will use Affymetrix’s GeneChip microarrays in translational research projects studying cancer and HIV and AIDS, Affy said today.
Under the terms of the agreement, VICC and Vanderbilt University Medical Center will use Affy’s mitochondrial resequencing array 2.0 as a tool to research genetic variants that may make patients more susceptible to adverse effects of certain drugs.
For cancer, Affy said VICC hopes that the studies will reveal the molecular basis of diseases and differences at the genetic level that influence responses to therapies. For HIV/AIDS research, the study aims to help clinicians determine the best drug treatments in “affluent and resource-limited settings.”
Jeff Canter, a researcher at the Center for Human Genetics Research and Vanderbilt, said ongoing translational projects include cancer, HIV/AIDS drug toxicities,” and macular degeneration.
Financial terms of the agreement were not released.